Cytoreduction for Pseudomyxoma Peritoneii
lnkd.in/d7sNRRuC
Read our study where we analyzed a cohort of over 200 patients who underwent curative-intent cytoreductive surgery (CRS) for pseudomyxoma peritonei (PMP).
@indepso@PSOGI_EC@JofSurgOnc@ACTREC_TMC
How much of the peritoneal surface are we really seeing?
In CRS, we focus on removing visible disease.
But what about the spaces we don't routinely explore?
At OGP 2026, Dr. Aditi Bhatt 🇮🇳 takes a closer look at:
“Revised Classification of Peritonectomy Procedures & Exploration of Occult Peritoneal Spaces.”
Can redefining peritonectomy and understanding occult spaces improve the completeness of cytoreduction?
A surgical anatomy discussion with implications far beyond anatomy.
📍 Pune | 📅 18–19 Sept 2026
🎟️ Register:
ogp2026.com/registration/det…#OGP2026#CRS#HIPEC#PeritonealSurfaceOncology#Peritonectomy#SurgicalOncology
Advanced pseudomyxoma peritonei isn't just about removing more disease—it's about making the right decisions.
When is surgery still worthwhile?
Can complete cytoreduction be achieved?
How do disease burden, anatomy, patient fitness, and biology influence outcomes?
Join Dr. Avanish Saklani as moderator for a high-impact Panel Discussion on Advanced Pseudomyxoma Peritonei at OGP 2026.
Hear leading experts discuss challenging cases, controversial scenarios, and the practical decision-making that defines modern CRS & HIPEC.
If you manage patients with peritoneal surface malignancies, this is a discussion you won't want to miss.
📍 OGP 2026 | Pune
📅 17–19 September 2026
🎟️ Register now:
ogp2026.com/registration/det…#OGP2026#PMP#PseudomyxomaPeritonei#CRS#HIPEC#PeritonealSurfaceOncology#PanelDiscussion#AvanishSaklani#SurgicalOncology#CancerSurgery@zeebausofi@writeslkpushkin@vivekanandkem@Bhandoria@Snioncosurgeon1
When pseudomyxoma peritonei is extensive, every decision carries weight.
How much disease is too much?
When should surgery be attempted?
How do we balance radicality with safety?
And what separates a successful cytoreduction from an incomplete one?
These are the questions that define outcomes—not just operative skill.
At OGP 2026, we're privileged to welcome Prof. @glehenolivier 🇫🇷, one of the world's leading authorities in Peritoneal Surface Oncology, for a thought-provoking session:
"Huge PMP: Critical Clinical Decisions."
Drawing on decades of experience in CRS & HIPEC, Prof. Glehen will share practical insights into managing some of the most challenging cases in surgical oncology, where anatomy is distorted, decisions are complex, and surgical judgement is everything.
Whether you're a surgical oncologist, gynecologic oncologist, medical oncologist, or trainee, this is a session you won't want to miss.
📍 OGP 2026 | Pune, India
📅 17–19 September 2026
🎟️ Register now:
ogp2026.com/registration/det…#OGP2026#PMP#PseudomyxomaPeritonei#CRS#HIPEC#PeritonealSurfaceOncology#OlivierGlehen#SurgicalOncology#CancerSurgery#MedicalEducation@zeebausofi@PSOGI_EC
How far is too far?
As the boundaries of cytoreductive surgery continue to evolve, one question remains at the heart of every operation:
Who should we operate on?
Join Prof. @LanaBijelicMD as she explores one of the most thought-provoking topics in Peritoneal Surface Oncology:
Selecting Patients for Cytoreductive Surgery: Extending Indications
Discover how evidence, experience, and surgical judgement come together to define the right patient for the right operation.
If you're involved in CRS & HIPEC, this is a session you won't want to miss.
📍 OGP 2026 | Pune
📅 17–19 September 2026
🎟️ Secure your seat today and learn from one of the world's foremost experts in Peritoneal Surface Oncology.
👉 ogp2026.com/registration/det…#OGP2026#CRS#HIPEC#PeritonealSurfaceOncology#SurgicalOncology#LanaBijelic#CancerSurgery#MedicalEducation#RegisterNow@zeebausofi
CRS & HIPEC demands more than technical skill.
It demands systems, structure, judgement, and relentless academic rigor.
Honoured to welcome Prof. @LanaBijelicMD
Chief, Peritoneal Surface Malignancies Unit, CHU Moisés Broggi, Barcelona
Academic Coordinator, ESPSO
A global leader helping shape modern Peritoneal Surface Oncology through education and multidisciplinary collaboration.
📍 Pune, India
📅 17–19 September 2026
Register:ogp2026.com/registration/det…#CRS#HIPEC#LanaBijelic#PeritonealSurfaceOncology#SurgicalOncology#OGP2026
When CRS gets difficult, textbooks stop helping.
That’s where surgical judgement begins.
Excited to welcome Prof. @artemstepanyan to the 3rd Biennial Conference of the Oncology Group of Pune.
Known for expertise in complex abdominal oncology and advanced cytoreductive surgery, his work reflects the precision and adaptability modern Peritoneal Surface Oncology demands.
📍 Pune, India
📅 17–19 September 2026
Register:ogp2026.com/registration/det…#CRS#HIPEC#ArtemStepanyan#PeritonealSurfaceOncology#SurgicalOncology#OGP2026
Honored to join the international faculty at OGP 2026 in Pune, India.
Looking forward to an inspiring meeting on peritoneal surface oncology, CRS, HIPEC and surgical education.
Thank you INDEPSO/SPSOI and the organizing committee.
CRS & HIPEC is easy on slides.
Reality begins when planes disappear, resections get complex, and judgement matters more than theory.
Honoured to welcome Prof. @glehenolivier — one of the global leaders in Peritoneal Surface Oncology — to the 3rd Biennial Conference of the Oncology Group of Pune.
A surgeon whose work has helped define modern standards in CRS, HIPEC, and complex peritonectomy surgery worldwide.
📍 Pune, India
📅 17–19 September 2026
Register here: ogp2026.com/registration/det…#CRS#HIPEC#OlivierGlehen#PeritonealSurfaceOncology#SurgicalOncology#OGP2026
Anyone can quote Sugarbaker scores in a conference hall.
The real test begins when the abdomen is open, the planes are obliterated, the disease is everywhere, and your team still has to deliver a safe, complete cytoreduction.
CRS & HIPEC is not surgical tourism.
It is not “advanced debulking.”
And it definitely isn’t for centres chasing trends without understanding the brutality of the learning curve.
Because this is what the textbooks don’t prepare you for:
▪️ Distorted anatomy
▪️ Endless peritonectomy planes
▪️ Massive resections
▪️ Fluid shifts and physiology under siege
▪️ Team fatigue
▪️ Complications that demand experience, not panic
The difference between average and exceptional outcomes is rarely knowledge alone.
It is operative judgement under pressure.
This workshop is built around the uncomfortable realities of CRS & HIPEC — where theory meets tissue, and where surgical oncology becomes very, very real.
#CRS#HIPEC#PeritonealSurfaceMalignancy#SurgicalOncology#GynecologicOncology#CancerSurgery#OncoSurgery#Peritonectomy#MedicalEducation#CadavericWorkshop@PSugarbaker@glehenolivier@writeslkpushkin@MufaddalKazi@zeebausofi@vivekanandkem@sukumar_vivek@Bhandoria@Snioncosurgeon1@docswapnil01
Speaker Spotlight | Prof. @PSugarbaker
Few names have shaped Peritoneal Surface Oncology the way Prof. Paul Sugarbaker has.
Widely regarded as the pioneer of Cytoreductive Surgery (CRS) and HIPEC, his work transformed what was once considered terminal peritoneal disease into a field of aggressive, biology-driven surgical oncology with meaningful long-term outcomes.
From establishing the principles of peritonectomy to redefining surgical strategies for peritoneal malignancies, generations of surgeons across the world continue to learn from his vision, techniques, and relentless pursuit of oncologic precision.
We are honoured to welcome Prof. Sugarbaker as part of the international faculty at the
3rd Biennial Conference of the Oncology Group of Pune.
Conference Highlights:
▪️ Cadaveric Workshop
▪️ Didactic Lectures & Panel Discussions
▪️ Stellar International & National Faculty
▪️ Live Pathology Workshop
📍 Pune, India
📅 17–19 September 2026
Register now:
OGP 2026 Registration: ogp2026.com/registration/det…#CRS#HIPEC#PaulSugarbaker#PeritonealSurfaceOncology#SurgicalOncology#CancerSurgery#GynecologicOncology#OncoSurgery#MedicalTwitter#CadavericWorkshop
KSERS2026
Good to be back to Seoul after a couple of year with colleagues and Fellows
Met Mentors and overseas colleagues.
Presented our institutional work on Minimally invasive work in colorectal cancers @TataMemorial@ACTREC_TMC